Table 2.
Studies investigating the impact of silymarin on survival in patients with cirrhosis
Data from [13], adapted with permission from Saller et al. [13]
| References | Silymarin dose (mg/day) | n | Patient/disease characteristics | Treatment duration (mo) | Liver-related mortality | |
|---|---|---|---|---|---|---|
| Silymarin (% patients) | Placebo (% patients) | |||||
| Ferenci et al. [55] | 420 | 170 |
Liver cirrhosis etiology: alcoholic/non-alcoholic 92/78 Child classification: A, 89; B, 69; C, 12 |
24 | 18.4a | 37.3 |
| Trinchet et al. [58] | 420 | 116 |
Alcoholic hepatitis, 58 with cirrhosis Baseline histology scores: fibrosis, 3; alcoholic hepatitis, 5 |
3 | 1.8 | 5.1 |
| Bunout et al. [60] | 280 | 71 | Alcoholic hepatic insufficiency (24/29 patients with biopsy data had cirrhosis) | 15 | 13.2 | 12.2 |
| Pares et al. [57] | 450 | 200 |
Alcoholic cirrhosis Child classification (Silymarin/Placebo): A, 37.9%/24.7%; B, 51.5%/62.9%; C, 6.8%/7.2% |
24 | 9.4 | 14.6 |
| Total Saller et al. (systematic review) [13] | 280–450 | 545 | – | 3–24 | 10.0a | 17.3 |
aP < 0.01 vs. placebo